Matteo Paz, an 18-year-old from Pasadena, California, has won the top prize of $250,000 in the 2025 Regeneron Science Talent Search. This competition is the oldest and most respected science and math contest for high school seniors in the United States. The announcement was made by Regeneron Pharmaceuticals, Inc. and the Society for Science on March 11, 2025.
Matteo Paz has won the top prize of $250,000 in the most prestigious and longest-running science and math competition in the United States. This award highlights his exceptional skills in these fields.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will participate in the Leerink Partners 2025 Global Healthcare Conference Call on March 11, 2025, at 8:00 AM ET. The company will be represented by Ryan Crowe, Senior Vice President of Investor Relations and Strategic Analysis, and Chris Fenimore, Chief Financial Officer. David Risinger from Leerink Partners will also be part of the call.
On Monday, March 10, the S&P 500 fell by 2.7% due to increased economic uncertainty caused by U.S. tariffs and cuts in government jobs, raising worries about a possible recession.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135096&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: The Rosen Law Firm, an international law firm focused on investor rights, is reminding buyers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities from November 2, 2023, to October 30, 2024, that the deadline to become a lead plaintiff is March 10, 2025.
Investors can reach out to the law firm for free to find out how they can recover their losses.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135082&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135049&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP informs investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) about a class action lawsuit related to securities.